# US 10,369,117 B2 · Compositions comprising mixtures of semifluorinated alkanes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,117 B2
- Document ID: US10369117B2
- Status: Granted
- Kind: B2
- Application number: 15/712,053
- Filed: 2017-09-21
- Published: 2018-03-15
- Granted: 2019-08-06
- Earliest claimed: 2012-09-12
- Assignees: Novaliq GmbH
- Applicants: Novaliq GmbH
- Inventors: Bernhard Günther; Bastian Theisinger; Sonja Theisinger; Dieter Scherer
- Web page: https://patentgrep.com/patent/US10369117B2

## CPC

- A61K 31/02: Halogenated hydrocarbons
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

## Claims

### Claim 1

A method for treating Meibomian Gland Dysfunction, comprising administering, to a patient in need thereof, a composition comprising a liquid semifluorinated alkane to the surface of the cornea and/or conjunctiva; and
wherein the semifluorinated alkane is F(CF2)6(CH2)8H; and
wherein said composition is effective in spreading out over the corneal and conjunctival surface and penetrating the Meibomian gland and/or Meibomian gland ducts, and wherein said composition is effective solubilizing the abnormal Meibomian secretions of said patient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said abnormal Meibomian secretions exhibit an increased viscosity and/or contain particulate cellular material.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said abnormal Meibomian secretions obstruct the Meibomian gland ducts.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said abnormal Meibomian secretions are ineffective in forming a functional stable and continuous tear film lipid layer and/or result in lipid tear film deficiency.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the patient's Meibomian Gland Dysfunction is associated with keratoconjunctivitis sicca (dry eye disease), or evaporative dry eye disease.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition solubilizes meibum lipids and removes abnormal and obstructive meibum from clogged Meibomian gland ducts.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition consists of F(CF2)6(CH2)8H.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition is free of any active ingredients.